A Single-Dose Study of LY3471851 in Healthy Participants
- Registration Number
- NCT04998487
- Lead Sponsor
- Nektar Therapeutics
- Brief Summary
The main purpose of this study is to estimate how much LY3471851 gets into the blood stream and how long it takes the body to remove it when administered under the skin in healthy participants. The study will also evaluate the safety and tolerability of LY3471851. The study is expected to last up to 87 days for each participant.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 71
Inclusion Criteria
- Overtly healthy males or females, as determined by medical history and physical examination.
- Body weight greater than 55 kilograms (kg) and body mass index (BMI) within the range of 19 to 30 kilograms per meter squared (kg/m²)
Exclusion Criteria
- Have evidence of clinically significant active infection, including fever 100.5ºF (38ºC) or above, within 28 days of dosing or Day 1 (before dosing)
- Have had serious, opportunistic, or chronic/recurring infection within 6 months prior to screening. Examples include but are not limited to infections requiring intravenous antibiotics, hospitalization, or prolonged treatment
- Are immunocompromised per investigator judgment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description LY3471851 (Abdomen) LY3471851 LY3471851 administered subcutaneously (SC) into the abdomen. LY3471851 (Thigh) LY3471851 LY3471851 administered SC into the thigh.
- Primary Outcome Measures
Name Time Method Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3471851 Predose up to 56 days postdose PK: Cmax of LY3471851
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3471851 Predose up to 56 days postdose PK: AUC of LY3471851
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
LabCorp CRU, Inc.
🇺🇸Daytona Beach, Florida, United States